Armstrong A[au] - Search Results

Year	Number of Results
1823	1
1912	2
1924	1
1925	2
1932	2
1933	1
1934	2
1935	3
1941	1
1945	1
1947	6
1948	2
1949	3
1950	1
1951	6
1953	1
1954	1
1955	2
1957	1
1960	5
1962	1
1964	9
1965	2
1966	3
1967	2
1970	3
1971	2
1972	2
1973	2
1975	2
1976	1
1977	1
1978	4
1979	2
1980	1
1981	1
1982	1
1984	4
1985	2
1986	8
1987	5
1988	4
1989	8
1990	8
1991	11
1992	13
1993	7
1994	11
1995	8
1996	15
1997	18
1998	11
1999	13
2000	12
2001	11
2002	13
2003	10
2004	28
2005	22
2006	22
2007	41
2008	43
2009	33
2010	55
2011	83
2012	94
2013	111
2014	105
2015	106
2016	111
2017	115
2018	129
2019	148
2020	149
2021	84

1

Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.

Armstrong AW, Read C. Armstrong AW, et al. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. JAMA. 2020. PMID: 32427307 Review.

2

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. Robson ME, et al. Among authors: armstrong a. Ann Oncol. 2019 Apr 1;30(4):558-566. doi: 10.1093/annonc/mdz012. Ann Oncol. 2019. PMID: 30689707 Free PMC article. Clinical Trial.

3

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.

Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, Armstrong AW, Connor C, Cordoro KM, Davis DMR, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kavanaugh A, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Rupani RN, Siegel M, Wong EB, Wu JJ, Hariharan V, Elmets CA. Menter A, et al. Among authors: armstrong aw. J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13. J Am Acad Dermatol. 2019. PMID: 30772098 Review.

4

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. Mohler JL, et al. Among authors: armstrong aj. J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023. J Natl Compr Canc Netw. 2019. PMID: 31085757

5

Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.

Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Betts KA, Augustin M. Armstrong AW, et al. JAMA Dermatol. 2020 Mar 1;156(3):258-269. doi: 10.1001/jamadermatol.2019.4029. JAMA Dermatol. 2020. PMID: 32022825 Free PMC article.

6

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.

Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S, Hsu MC, Branigan P, Blauvelt A. Reich K, et al. Among authors: armstrong aw. Lancet. 2019 Sep 7;394(10201):831-839. doi: 10.1016/S0140-6736(19)31773-8. Epub 2019 Aug 8. Lancet. 2019. PMID: 31402114 Clinical Trial.

7

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.

Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Elmets CA, et al. Among authors: armstrong aw. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113. doi: 10.1016/j.jaad.2018.11.058. Epub 2019 Feb 13. J Am Acad Dermatol. 2019. PMID: 30772097 Review.

8

Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.

Florek AG, Wang CJ, Armstrong AW. Florek AG, et al. Among authors: armstrong aw. Arch Dermatol Res. 2018 May;310(4):271-319. doi: 10.1007/s00403-018-1808-x. Epub 2018 Feb 13. Arch Dermatol Res. 2018. PMID: 29442137 Review.

9

Updates in advanced prostate cancer 2018.

Armstrong AJ. Armstrong AJ. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):449-450. doi: 10.1038/s41391-018-0100-7. Epub 2018 Oct 2. Prostate Cancer Prostatic Dis. 2018. PMID: 30279577 No abstract available.

10

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.

Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK, Gordon KB. Reich K, et al. Among authors: armstrong aw. J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2. J Am Acad Dermatol. 2017. PMID: 28057361 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results